BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32972785)

  • 1. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
    Kortekaas KE; Bastiaannet E; van Doorn HC; de Vos van Steenwijk PJ; Ewing-Graham PC; Creutzberg CL; Akdeniz K; Nooij LS; van der Burg SH; Bosse T; van Poelgeest MIE
    Gynecol Oncol; 2020 Dec; 159(3):649-656. PubMed ID: 32972785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma.
    Dongre HN; Elnour R; Tornaas S; Fromreide S; Thomsen LCV; Kolseth IBM; Nginamau ES; Johannessen AC; Vintermyr OK; Costea DE; Bjørge L
    Acta Obstet Gynecol Scand; 2024 Jan; 103(1):165-175. PubMed ID: 37840151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.
    Kortekaas KE; Santegoets SJ; Abdulrahman Z; van Ham VJ; van der Tol M; Ehsan I; van Doorn HC; Bosse T; van Poelgeest MIE; van der Burg SH
    J Immunother Cancer; 2019 Sep; 7(1):236. PubMed ID: 31481117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer.
    Sznurkowski JJ; Żawrocki A; Biernat W
    BMC Cancer; 2016 Jul; 16():465. PubMed ID: 27411473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers p16, Human Papillomavirus and p53 Predict Recurrence and Survival in Early Stage Squamous Cell Carcinoma of the Vulva.
    Hay CM; Lachance JA; Lucas FL; Smith KA; Jones MA
    J Low Genit Tract Dis; 2016 Jul; 20(3):252-6. PubMed ID: 26855143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study.
    McAlpine JN; Leung SCY; Cheng A; Miller D; Talhouk A; Gilks CB; Karnezis AN
    Histopathology; 2017 Aug; 71(2):238-246. PubMed ID: 28257152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification of Vulvar Squamous Cell Carcinoma and Precursor Lesions by p16 and p53 Immunohistochemistry: Considerations, Caveats, and an Algorithmic Approach.
    Yang H; Almadani N; Thompson EF; Tessier-Cloutier B; Chen J; Ho J; Senz J; McConechy MK; Chow C; Ta M; Cheng A; Karnezis A; Huvila J; McAlpine JN; Gilks B; Jamieson A; Hoang LN
    Mod Pathol; 2023 Jun; 36(6):100145. PubMed ID: 36828360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular events in the pathogenesis of vulvar squamous cell carcinoma.
    Xing D; Fadare O
    Semin Diagn Pathol; 2021 Jan; 38(1):50-61. PubMed ID: 33032902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group.
    Woelber L; Prieske K; Eulenburg C; Oliveira-Ferrer L; de Gregorio N; Klapdor R; Kalder M; Braicu I; Fuerst S; Klar M; Strauss HG; Beckmann M; Meier W; Ignatov A; Mustea A; Jueckstock J; Schmidt G; Bauerschlag D; Hellriegel M; Canzler U; Petry KU; Kommoss S; Hantschmann P; Heubner M; Mahner S; Burandt E
    Am J Obstet Gynecol; 2021 Jun; 224(6):595.e1-595.e11. PubMed ID: 33453182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Squamous Cell Carcinoma of the Vulva: A Subclassification of 97 Cases by Clinicopathologic, Immunohistochemical, and Molecular Features (p16, p53, and EGFR).
    Dong F; Kojiro S; Borger DR; Growdon WB; Oliva E
    Am J Surg Pathol; 2015 Aug; 39(8):1045-53. PubMed ID: 26171917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus (HPV) and HPV 16-variant distribution in vulvar squamous cell carcinoma in Sweden.
    Larsson GL; Helenius G; Andersson S; Elgh F; Sorbe B; Karlsson MG
    Int J Gynecol Cancer; 2012 Oct; 22(8):1413-9. PubMed ID: 23013732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus and p53 status define three types of vulvar squamous cell carcinomas with distinct clinical, pathological, and prognostic features.
    Carreras-Dieguez N; Saco A; Del Pino M; Marimon L; López Del Campo R; Manzotti C; Fusté P; Pumarola C; Torné A; Garcia A; Rakislova N
    Histopathology; 2023 Jul; 83(1):17-30. PubMed ID: 37099408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors.
    Allo G; Yap ML; Cuartero J; Milosevic M; Ferguson S; Mackay H; Kamel-Reid S; Weinreb I; Ghazarian D; Pintilie M; Clarke BA
    Int J Gynecol Pathol; 2020 Jul; 39(4):391-399. PubMed ID: 31274700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases.
    Cheng AS; Karnezis AN; Jordan S; Singh N; McAlpine JN; Gilks CB
    Int J Gynecol Pathol; 2016 Jul; 35(4):385-93. PubMed ID: 26630231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of p16 and p53 expression for survival after vulvar cancer: A systematic review and meta-analysis.
    Sand FL; Nielsen DMB; Frederiksen MH; Rasmussen CL; Kjaer SK
    Gynecol Oncol; 2019 Jan; 152(1):208-217. PubMed ID: 30415992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV status and favourable outcome in vulvar squamous cancer.
    Wakeham K; Kavanagh K; Cuschieri K; Millan D; Pollock KG; Bell S; Burton K; Reed NS; Graham SV
    Int J Cancer; 2017 Mar; 140(5):1134-1146. PubMed ID: 27864932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
    Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
    Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
    Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
    Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3.
    Weberpals JI; Lo B; Duciaume MM; Spaans JN; Clancy AA; Dimitroulakos J; Goss GD; Sekhon HS
    Clin Cancer Res; 2017 Aug; 23(15):4501-4510. PubMed ID: 28377483
    [No Abstract]   [Full Text] [Related]  

  • 20. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status.
    Tessier-Cloutier B; Kortekaas KE; Thompson E; Pors J; Chen J; Ho J; Prentice LM; McConechy MK; Chow C; Proctor L; McAlpine JN; Huntsman DG; Gilks CB; Bosse T; Hoang LN
    Mod Pathol; 2020 Aug; 33(8):1595-1605. PubMed ID: 32203095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.